Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Xavier Packianathan

Vascular & Interventional Radiology Tamuning, GU Medical Doctor

NPI 1669692059 CMS profile 211968

633 Gov Carlos Camacho Rd, Suite 210, Tamuning, GU 96913

Open in the dashboard

General payments

$5,634

69 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Xavier Packianathan of Tamuning, GU is reported in the CMS Open Payments database as having received $5,634 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,905 16
2024 General $515 9
2023 General $2,005 25
2022 General $184 5
2021 General $575 10
2020 General $450 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Xavier Packianathan
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Xavier Packianathan were reported at $1,905. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Xavier Packianathan Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $450 $200 $68–$652 $114
2021 $575 $280 $99–$866 $132
2022 $184 $433 $137–$1,497 $149
2023 $2,005 $506 $152–$2,019 $160
2024 $515 $556 $175–$1,930 $164
2025 $1,905 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $1,696 11 payments
  2. Boston Scientific Corporation $1,533 15 payments
  3. Stryker Corporation $841 4 payments
  4. Cardiovascular Systems Inc. $425 3 payments
  5. Bard Peripheral Vascular, Inc. $330 18 payments
  6. Penumbra, Inc. $322 4 payments
  7. Cordis US Corp. $118 2 payments
  8. AngioDynamics, Inc. $114 2 payments
  9. Inari Medical, Inc. $70 3 payments
  10. Abbott Laboratories $61 2 payments
  11. Other $125 5 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $3,191 11 payments
  2. Food and Beverage $2,444 58 payments
Products named General payments · program years 2020–2025
  1. OSTEOCOOL RF ABLATION SYSTEM $1,522 6 payments
  2. ICEfx Cryoablation System $1,020 7 payments
  3. FLOWTRIEVER CATHETER, S $590 6 payments
  4. CT THROMBECTOMY SYSTEM KIT $493 2 payments
  5. Peripheral Orbital Atherectomy System $425 3 payments
  6. SPINEJACK $369 3 payments
  7. Indigo System $290 3 payments
  8. EMBOLD Fibered $131 3 payments
  9. General - Therapies $121 2 payments
  10. COVERA $98 6 payments
  11. Other $823 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 159 billing codes

Paid by Medicare

$122,222

Of which drugs: $2,147

Medicare patients

680

Average age 71

Services billed

15,301

338 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Chronic kidney disease 48%
Ischemic heart disease 44%
Arthritis 39%
Heart failure 33%
COPD 25%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 97 11,124 $982
Injection, gadoterate meglumine, 0.1 ml A9575 Office 18 2,610 $207

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Guam

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record